---
title: "Antidepressant Side-Effects: Cardiometabolic & Physiological Guide"
# slug: "antidepressant-side-effects"
description: "How common antidepressants differ on weight, blood pressure, heart rate, cholesterol/glucose, liver enzymes, electrolytes, and QTc — plus monitoring and safer choices by risk profile."
category: "Mental Health"
publishDate: "2025-10-23"
tags: ["antidepressants", "side-effects", "cardiometabolic", "metabolic-health"]
draft: false
---

import Callout from "@/components/Callout.astro"
import StatBox from "@/components/StatBox.astro"
import EvidenceBox from "@/components/EvidenceBox.astro"
import DrugCompare from "@/components/DrugCompare.astro"
import RiskBadge from "@/components/RiskBadge.astro"

## Intro
Antidepressants can shift **weight**, **blood pressure (BP)**, **heart rate (HR)**, **lipids/glucose**, and **liver enzymes** — and the pattern differs by drug/class. Short-term RCTs show meaningful spreads in these parameters across agents, which matters for people with **obesity, hypertension, diabetes risk, or dyslipidemia**.

---

## Key Points
- Expect **≈4 kg** spread in short-term weight change, **~20 bpm** spread in HR, **~11 mmHg** spread in systolic BP across agents.  
- **SNRIs** (venlafaxine, desvenlafaxine, duloxetine, levomilnacipran): ↑ **BP** and **cholesterol**; duloxetine → ↑ **glucose** and small ↑ **AST/ALT**.  
- **TCAs** (amitriptyline, imipramine, maprotiline): ↑ **HR/BP** and **weight**.  
- **Agomelatine**, **fluoxetine**, **bupropion**: more favorable **weight** profiles short-term.  
- Minimal QTc/sodium signal in RCTs; real-world risk rises in **older, multimorbid** adults.

<Callout type="info">
  <strong>At a glance:</strong> Choose by both <em>brain</em> and <em>body</em> profile — not just symptom efficacy — to reduce discontinuation and downstream cardiovascular risk.
</Callout>

<div className="my-6 grid gap-3 sm:grid-cols-3">
  <StatBox value="–2.4 kg" label="Agomelatine — short-term weight" />
  <StatBox value="+13 bpm" label="Nortriptyline — heart rate" />
  <StatBox value="+3–5 mmHg" label="SNRIs/TCAs — systolic BP" />
</div>

<EvidenceBox
  title="Key Evidence — Network Meta-Analysis"
  date="2025-10-21"
  source="Pillinger et al., The Lancet"
  findings={[
    "151 RCTs; ~58,500 participants; 30 antidepressants compared for physiological outcomes.",
    "SNRIs: ↑ cholesterol and BP; duloxetine: ↑ glucose and LFTs (small).",
    "TCAs: ↑ HR/BP and weight; agomelatine/fluoxetine/bupropion: favorable weight.",
    "Short-term RCTs show minimal QTc/sodium signal."
  ]}
/>

---

## Options by Clinical Profile
- **Metabolic risk (obesity, T2D, dyslipidemia):** prefer **Agomelatine**, **Fluoxetine**, **Bupropion**.  
- **Hypertension/CVD:** avoid agents with BP/HR rises (**Venlafaxine / Desvenlafaxine / Duloxetine**, **Levomilnacipran**, many **TCAs**).  
- **Weight gain concern:** avoid **Mirtazapine**, **Amitriptyline**, **Maprotiline**.  
- **Older adults/polypharmacy:** start low, go slow; consider **Na⁺** and **QTc** monitoring even if RCT signal is minimal.

<DrugCompare
  drugs={[
    { name: "Agomelatine", brand: "Valdoxan", level: "low", weight: "↓ ~2.4 kg", cardio: "Neutral", metabolic: "Neutral" },
    { name: "Fluoxetine", brand: "Prozac", level: "low", weight: "↓ ~0.8 kg", cardio: "Neutral", metabolic: "Neutral" },
    { name: "Bupropion", brand: "Wellbutrin", level: "low", weight: "↓ / neutral", cardio: "Neutral", metabolic: "Neutral" },
    { name: "Venlafaxine", brand: "Effexor", level: "moderate", weight: "neutral", cardio: "↑ BP", metabolic: "↑ Cholesterol" },
    { name: "Desvenlafaxine", brand: "Pristiq", level: "moderate", weight: "neutral", cardio: "↑ BP", metabolic: "↑ Cholesterol" },
    { name: "Duloxetine", brand: "Cymbalta", level: "moderate", weight: "↓ (small)", cardio: "↑ BP", metabolic: "↑ Chol/Glucose" },
    { name: "Levomilnacipran", brand: "Fetzima", level: "moderate", weight: "neutral", cardio: "↑ BP", metabolic: "↑ LFTs (small)" },
    { name: "Amitriptyline", brand: "Elavil", level: "high", weight: "↑ ~1.5–1.6 kg", cardio: "↑ HR/BP", metabolic: "↑ Lipids" },
    { name: "Mirtazapine", brand: "Remeron", level: "high", weight: "↑", cardio: "Neutral/↑ HR", metabolic: "↑ Lipids (some data)" },
    { name: "Maprotiline", brand: "Ludiomil", level: "high", weight: "↑ ~1.8 kg", cardio: "↑ HR/BP", metabolic: "↑ Lipids" }
  ]}
/>

---

## Monitoring (first 8–12 weeks)
- **Baseline → week 4 → week 8:** weight/waist, BP, HR.  
- **Labs:** fasting **lipids & glucose** (SNRIs or metabolic risk); **LFTs** (duloxetine/desvenlafaxine/levomilnacipran or hepatic history).  
- **Electrolytes (Na⁺)** and **ECG (QTc)** for older adults or those on QT-prolongers/diuretics.

---

## Generic → Trade names (quick map)
**SSRIs:** Fluoxetine (*Prozac*), Sertraline (*Zoloft*), Paroxetine (*Paxil*), Citalopram (*Celexa*), Escitalopram (*Lexapro*), Fluvoxamine (*Luvox*)  
**SNRIs:** Venlafaxine (*Effexor*), Desvenlafaxine (*Pristiq*), Duloxetine (*Cymbalta*), Levomilnacipran (*Fetzima*)  
**Atypical:** Bupropion (*Wellbutrin*), Agomelatine (*Valdoxan*), Mirtazapine (*Remeron*)  
**TCAs:** Amitriptyline (*Elavil*), Nortriptyline (*Pamelor*), Imipramine (*Tofranil*), Doxepin (*Sinequan*), Maprotiline (*Ludiomil*)

---

## FAQ
**Do SSRIs behave the same?**  
No. **Paroxetine** shows more lipid impact; **fluoxetine/sertraline/escitalopram** look more neutral short-term.

**If weight falls early, will it stay down?**  
Not guaranteed. Longer observational cohorts often show net gain with chronic use.

**Any big QTc/sodium issues?**  
Not in these RCTs; registry data in older, sicker patients still flags **hyponatremia** and **QT** concerns, so monitor when indicated.

---

## Further Reading
- Pillinger T, Arumuham A, McCutcheon RA, et al. *Lancet* (2025). doi:10.1016/S0140-6736(25)01293-0  
- NICE. Depression in adults: treatment and management.

{/* ====================== JSON-LD ====================== */}
<script type="application/ld+json">
{JSON.stringify({
  "@context": "https://schema.org",
  "@type": "MedicalWebPage",
  "name": "Antidepressant Side-Effects: Cardiometabolic & Physiological Guide",
  "description": "Comparative cardiometabolic and physiological side-effects of common antidepressants with monitoring guidance.",
  "datePublished": "2025-10-23",
  "dateModified": "2025-10-23",
  "breadcrumb": {
    "@type": "BreadcrumbList",
    "itemListElement": [
      {"@type":"ListItem","position":1,"name":"Home","item":"https://patientguide.io/"},
      {"@type":"ListItem","position":2,"name":"Guides","item":"https://patientguide.io/guides/"},
      {"@type":"ListItem","position":3,"name":"Antidepressant Side-Effects"}
    ]
  },
  "hasPart": {
    "@type": "FAQPage",
    "mainEntity": [
      {"@type":"Question","name":"Do SSRIs behave the same?","acceptedAnswer":{"@type":"Answer","text":"No. Paroxetine shows more lipid impact; fluoxetine, sertraline, and escitalopram appear more neutral in short-term RCTs."}},
      {"@type":"Question","name":"If weight falls early, will it stay down?","acceptedAnswer":{"@type":"Answer","text":"Not guaranteed. Longer observational cohorts often show net gain with chronic use; monitor and match by risk profile."}},
      {"@type":"Question","name":"Any big QTc or sodium issues?","acceptedAnswer":{"@type":"Answer","text":"Short-term RCTs show minimal signal; registry studies in older, multimorbid adults still flag hyponatremia and QT concerns."}}
    ]
  },
  "mentions": [
    {"@type":"Drug","name":"Fluoxetine","brand":"Prozac","drugClass":"SSRI"},
    {"@type":"Drug","name":"Sertraline","brand":"Zoloft","drugClass":"SSRI"},
    {"@type":"Drug","name":"Paroxetine","brand":"Paxil","drugClass":"SSRI"},
    {"@type":"Drug","name":"Citalopram","brand":"Celexa","drugClass":"SSRI"},
    {"@type":"Drug","name":"Escitalopram","brand":"Lexapro","drugClass":"SSRI"},
    {"@type":"Drug","name":"Fluvoxamine","brand":"Luvox","drugClass":"SSRI"},
    {"@type":"Drug","name":"Venlafaxine","brand":"Effexor","drugClass":"SNRI"},
    {"@type":"Drug","name":"Desvenlafaxine","brand":"Pristiq","drugClass":"SNRI"},
    {"@type":"Drug","name":"Duloxetine","brand":"Cymbalta","drugClass":"SNRI"},
    {"@type":"Drug","name":"Levomilnacipran","brand":"Fetzima","drugClass":"SNRI"},
    {"@type":"Drug","name":"Bupropion","brand":"Wellbutrin","drugClass":"Atypical"},
    {"@type":"Drug","name":"Agomelatine","brand":"Valdoxan","drugClass":"Atypical"},
    {"@type":"Drug","name":"Mirtazapine","brand":"Remeron","drugClass":"Atypical"},
    {"@type":"Drug","name":"Amitriptyline","brand":"Elavil","drugClass":"TCA"},
    {"@type":"Drug","name":"Nortriptyline","brand":"Pamelor","drugClass":"TCA"},
    {"@type":"Drug","name":"Imipramine","brand":"Tofranil","drugClass":"TCA"},
    {"@type":"Drug","name":"Doxepin","brand":"Sinequan","drugClass":"TCA"},
    {"@type":"Drug","name":"Maprotiline","brand":"Ludiomil","drugClass":"TCA"}
  ],
  "citation": ["https://doi.org/10.1016/S0140-6736(25)01293-0"]
})}
</script>
